Archive: 07/09/2016

Eribulin in liposarcoma: Added benefit not proven

Eribulin (trade name: Halaven) has been approved since May 2016 for the treatment of adults with advanced liposarcoma. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment ...

Face transplants: the ups and downs

Ten years and 36 operations later, the face transplant remains a tricky endeavour with a long list of health and mental risks to be weighed against the benefits, experts say.

page 5 from 10